| SRZN |
Surrozen, Inc. |
Common Stock, par value $0.0001 per share |
11% |
$27,454,916 |
|
1,274,010 |
|
Chen Yu |
26 Jan 2026 |
| TNGX |
Tango Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
10% |
$158,881,608 |
+$58,581,305 |
13,521,839 |
+58% |
TCG Crossover GP II, L.P. |
31 Dec 2025 |
| RAPT |
RAPT Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
10% |
$11,478,006 |
|
13,193,110 |
|
TCG Crossover GP II, LLC |
27 Dec 2024 |
| IPSC |
Century Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$15,978,987 |
|
17,754,430 |
|
Chen Yu |
09 Jan 2026 |
| ALXO |
ALX Oncology Holdings Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$14,703,389 |
|
13,011,849 |
|
Chen Yu |
30 Jan 2026 |
| ADCT |
ADC Therapeutics SA |
Common Shares, par value CHF $0.08 per share |
9.2% |
$42,143,648 |
|
11,390,175 |
|
TCG Crossover GP II, LLC |
27 Oct 2025 |
| ALEC |
Alector, Inc. |
Common Stock, par value $0.0001 per share |
9.2% |
$29,600,000 |
|
10,000,000 |
|
Chen Yu |
22 Oct 2025 |
| ADVM |
Adverum Biotechnologies, Inc. |
Common Stock, par value $0.0001 per share |
8.9% |
|
|
1,871,482 |
|
TCG Crossover GP II, LLC |
31 Mar 2025 |
|
LB Pharmaceuticals Inc. |
Common Stock, par value $0.0001 per share |
7.8% |
|
|
1,745,015 |
|
TCG Crossover GP II, LLC |
12 Sep 2025 |
| GLUE |
Monte Rosa Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
7.2% |
$32,812,836 |
|
4,427,705 |
|
Chen Yu |
10 Oct 2025 |
| CATX |
Perspective Therapeutics, Inc. |
Common Stock, $0.001 par value |
6.9% |
$21,767,809 |
|
7,915,567 |
|
Chen Yu |
03 Feb 2026 |
| AMLX |
Amylyx Pharmaceuticals Inc. |
Common Stock, $0.0001 par value per share |
5.7% |
$74,863,306 |
|
6,243,812 |
|
TCG Crossover GP II, LLC |
31 Dec 2025 |
| DNTH |
Dianthus Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
4.7% |
$32,660,322 |
|
1,501,624 |
|
TCG Crossover GP II, LLC |
31 Mar 2025 |
| EYPT |
Eyepoint, Inc. |
Common Stock, $0.001 par value per share |
4.3% |
$62,265,799 |
|
3,572,335 |
|
TCG Crossover GP II, LLC |
31 Dec 2025 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
TCG Crossover GP II, LLC |
30 Sep 2025 |
| NKTR |
Nektar Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
-$110,015,928 |
0 |
-100% |
TCG Crossover GP II, LLC |
30 Sep 2025 |